Meanwhile, mutations of p53 are present in approximately half of all human cancers, including pancreatic adenocarcinoma, which results in loss of wild-type p53 function or gain of function that promotes cancer phenotypes [29]. This evidence concerns the gene TP53 and pancreatic adenocarcinoma.